Skip to main content
Top
Published in: International Urogynecology Journal 12/2016

01-12-2016 | Original Article

Quality of life outcomes in peri-urethral calcium hydroxylapatite injection

Authors: Meghan A. Griffin, Kirsten J. C. Janosek-Albright, Mireya Diaz-Insua, Solafa Elshatanoufy, Humphrey O. Atiemo

Published in: International Urogynecology Journal | Issue 12/2016

Login to get access

Abstract

Introduction and hypothesis

Peri-urethral calcium hydroxylapatite injection is an established treatment for patients with stress urinary incontinence. Information is limited regarding calcium hydroxylapatite treatment and quality of life (QOL) outcomes. We hypothesize that patients might improve QOL after peri-urethral calcium hydroxylapatite injection, which was reflected in validated questionnaires.

Methods

The peri-urethral calcium hydroxylapatite injection billing code was used to identify patients who underwent injection from 2011–2013. Female patients who completed the American Urological Association Symptom Score (AUASS), the AUASS QOL and Michigan Incontinence Symptom Index (M-ISI), and the bother score (M-ISI bother), or pad count at baseline and follow-up were included. Change in questionnaire scores and pads were assessed using the paired t test.

Results

Sixty patients underwent 1 (30), 2 (63) or 3 (7 %) peri-urethral calcium hydroxylapatite injections performed by a single surgeon. Thirty-seven patients provided questionnaires and 38 provided pad counts, all with a mean age of 75 years. The overall AUASS, AUASS QOL, and overall M-ISI scores improved in 67.6, 54.8, and 61.3 % respectively (4.5 ± 7.9, 1.3 ± 1.7 and 5.5 ± 8.6 respectively). The M-ISI bother score improved in 44.8 % with a mean improvement of 0.5 ± 2.9, but did not reach significance. There was a 1.7 ± 3.7 decrease in the mean number of pads used daily after the procedure (p = 0.006) and 19 % experienced transient urinary retention.

Conclusions

Peri-urethral calcium hydroxylapatite injections can improve urinary QOL scores in patients with initial and recurrent stress urinary incontinence. This short-term retrospective analysis suggests that larger long-term studies focusing on QOL outcomes are needed to evaluate the effect of peri-urethral calcium hydroxylapatite has on incontinence-specific QOL.
Appendix
Available only for authorised users
Literature
7.
8.
go back to reference Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, Graham CW, Snyder JA, Nitti VW, Winters JC (2007) Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology 69:876–880. doi:10.1016/j.urology.2007.01.050 CrossRefPubMed Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, Graham CW, Snyder JA, Nitti VW, Winters JC (2007) Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology 69:876–880. doi:10.​1016/​j.​urology.​2007.​01.​050 CrossRefPubMed
10.
go back to reference Chai TC, Belville WD, McGuire EJ, Nyquist L (1993) Specificity of the American urological association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 150:1710–1713PubMed Chai TC, Belville WD, McGuire EJ, Nyquist L (1993) Specificity of the American urological association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 150:1710–1713PubMed
11.
go back to reference Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148:1549–1557PubMed Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148:1549–1557PubMed
12.
go back to reference Gumus II, Kaygusuz I, Derbent A, Simavli S, Kafali H (2011) Effect of the Macroplastique implantation system for stress urinary incontinence in women with or without a history of an anti-incontinence operation. Int Urogynecol J 22:743–749. doi:10.1007/s00192-011-1398-z CrossRefPubMed Gumus II, Kaygusuz I, Derbent A, Simavli S, Kafali H (2011) Effect of the Macroplastique implantation system for stress urinary incontinence in women with or without a history of an anti-incontinence operation. Int Urogynecol J 22:743–749. doi:10.​1007/​s00192-011-1398-z CrossRefPubMed
16.
go back to reference Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S (2009) Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol 181:204–210. doi:10.1016/j.juro.2008.09.032 CrossRefPubMed Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S (2009) Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol 181:204–210. doi:10.​1016/​j.​juro.​2008.​09.​032 CrossRefPubMed
Metadata
Title
Quality of life outcomes in peri-urethral calcium hydroxylapatite injection
Authors
Meghan A. Griffin
Kirsten J. C. Janosek-Albright
Mireya Diaz-Insua
Solafa Elshatanoufy
Humphrey O. Atiemo
Publication date
01-12-2016
Publisher
Springer London
Published in
International Urogynecology Journal / Issue 12/2016
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3053-1

Other articles of this Issue 12/2016

International Urogynecology Journal 12/2016 Go to the issue

Urogynecology Digest

Urogynecology digest